Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide for Secondary CV Prevention

SELECT found a 1.5-point absolute difference in major cardiovascular events, while a 2026 NICE appraisal addresses the separate NHS access question.

Why we wrote this. A trial result and an NHS access decision are related, but they are not the same evidence question.

In this article (5 sections)
  1. SELECT tested people with existing cardiovascular disease
  2. Relative benefit did not erase treatment burden
  3. The 2026 UK appraisal adds an access question
  4. What the readout does and does not establish
  5. What we do not yet know

The SELECT trial found fewer major cardiovascular events with weekly semaglutide than placebo in adults who already had cardiovascular disease and had overweight or obesity, but did not have diabetes. Events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean 39.8 months of follow-up[1]. A 2026 Drug and Therapeutics Bulletin article reviews this secondary-prevention use against a new NICE appraisal, but the trial and appraisal answer different questions[2].

SELECT tested people with existing cardiovascular disease

SELECT enrolled 17,604 adults aged 45 or older. Everyone had preexisting cardiovascular disease and a body mass index of at least 27. A history of diabetes excluded participation. The randomized, double-blind trial compared weekly subcutaneous semaglutide 2.4 mg with placebo on top of usual care[1].

The primary outcome combined cardiovascular death, nonfatal heart attack, and nonfatal stroke. This was secondary prevention because participants already had cardiovascular disease. The result should not be generalized to people without established disease or treated as evidence that weight loss alone prevents a first event.

There were 569 primary events among 8,803 participants assigned to semaglutide and 701 among 8,801 assigned to placebo. The hazard ratio was 0.80, with a 95% confidence interval from 0.72 to 0.90[1]. That is a 20% relative hazard reduction. The observed absolute difference was 1.5 percentage points during the trial period.

Relative benefit did not erase treatment burden

Adverse events led to permanent treatment discontinuation in 16.6% of the semaglutide group and 8.2% of the placebo group[1]. SELECT therefore supports a cardiovascular benefit in its population, but it does not support presenting the medicine as a cost-free intervention.

Trial discontinuation is not the same as a complete adverse-event profile. It does show why an individual discussion must include tolerance and existing medicines. Contraindications and the likelihood of staying on treatment also matter. The trial abstract does not supply a single benefit-harm answer for every patient.

The 2026 UK appraisal adds an access question

NICE technology appraisal TA1152 considers semaglutide for reducing major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity[3]. Its committee papers examine SELECT alongside current care, eligibility, service delivery, and economic modelling. An appraisal decides whether and how the NHS should use a treatment. It is not a second efficacy trial.

That distinction matters because a statistically significant trial result does not automatically establish broad NHS access. NICE considers the licensed population and the population for whom use is cost effective. It can also specify conditions for treatment that are narrower than a medicine's authorization.

The Drug and Therapeutics Bulletin record is an evidence review with no abstract in PubMed. Crossref metadata shows that it cites SELECT, NICE TA1152, UK product information, and regulator material. Because its full text was not available to our verifier, we have not attributed any detailed conclusion to the bulletin beyond its title and bibliographic scope.

The appraisal evidence also makes the comparator question visible. SELECT compared semaglutide with placebo while both groups continued usual cardiovascular care. An NHS decision asks what adding semaglutide changes relative to current practice and what resources that addition requires. Those are not weaknesses in the trial. They are separate steps between an efficacy result and a health-service recommendation. Context matters.

Eligibility is equally specific. SELECT required both established cardiovascular disease and a BMI of at least 27, while excluding people with diabetes. Someone can have obesity without prior cardiovascular disease, or cardiovascular disease without meeting the trial's BMI threshold. Neither person is represented by the randomized population described here. The 20% relative hazard reduction should stay attached to the group that was actually enrolled.

What the readout does and does not establish

SELECT establishes that semaglutide reduced the trial's three-part cardiovascular composite in a defined high-risk population without diabetes. It does not show the same absolute benefit in someone with a different baseline risk. It also does not compare semaglutide with another GLP-1 medicine, a weight-management programme, or an alternative cardiovascular drug.

The trial should not be transferred automatically to oral semaglutide or to tirzepatide. Formulations, populations, comparator treatments, and outcome trials differ. Readers can review the wider semaglutide evidence page and the semaglutide regulation section.

What we do not yet know

The main trial does not tell us how long benefit persists after treatment stops. It cannot determine whether the cardiovascular effect was mediated by weight change, blood pressure, inflammation, or several pathways together. The average result also does not identify which eligible person is most likely to benefit or discontinue.

For UK readers, evidence and access must remain separate. SELECT supplies the outcome data. NICE supplies the current NHS recommendation and conditions. Product information supplies authorized use and safety wording. A clinician must then decide whether those boundaries fit the individual case.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What did SELECT find?

Major cardiovascular events occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo, a hazard ratio of 0.80.

Was SELECT a primary-prevention trial?

No. Participants already had cardiovascular disease, so the trial tested secondary prevention in adults with overweight or obesity and no diabetes.

Did the trial establish NHS access?

No. NICE separately assesses clinical evidence, cost effectiveness, and service conditions when making NHS recommendations.

Can the result be applied to every GLP-1 medicine?

No. The result belongs to weekly subcutaneous semaglutide in the SELECT population and cannot be transferred automatically to other formulations or medicines.

Sources

  1. [1]SELECT randomized cardiovascular outcomes trial. PMID 37952131.Tier 1 · primary↩
  2. [2]Drug and Therapeutics Bulletin record on semaglutide for secondary cardiovascular prevention. PMID 42994978.Tier 1 · primary↩
  3. [3]NICE TA1152: semaglutide for reducing major adverse cardiovascular events.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars